Q-omics provides the consensus-scored PLAC9P1 profile across patient tissues and cancer cell-line models. PLAC9P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PLAC9P1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PLAC9P1 RNA expression shows 13,822 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where PLAC9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAC9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAC9P1 survival associations across molecular data types. PLAC9P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAC9P1 RNA expression–survival associations across cancer types. High PLAC9P1 expression shows unfavorable associations in COAD and SKCM, but favorable associations in BRCA, LAML, STAD and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PLAC9P1 RNA expression.
This table summarizes PLAC9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLAC9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAC9P1 shows lower tumor expression in KIRC, KICH, COAD, THCA, BLCA and LUAD. The KIRC box plot shows higher PLAC9P1 RNA expression in normal versus tumor tissue (log2 FC = −0.642, t-test p < 0.001).
This table shows molecular features associated with PLAC9P1 in patient tissues and cancer cell lines. In patient samples, PLAC9P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
